Compare GraniteShares 2x Long COIN Daily ETF (CONL) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GraniteShares 2x Long COIN Daily ETF vs State Street SPDR S&P Biotech ETF — how do they compare? GraniteShares 2x Long COIN Daily ETF trades at $5.39 (market cap $510.01M), while State Street SPDR S&P Biotech ETF trades at $154.01 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 19.8× GraniteShares 2x Long COIN Daily ETF's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, GraniteShares 2x Long COIN Daily ETF nearer its low. Which is the better fit depends on your goals.
| CONL | XBI | |
|---|---|---|
Market Cap | $510.01M | $10.11B |
Volume | 21,041,836 | 12,903,266 |
Sector | Leveraged / Inverse | Broad Market / Factor |
52-Week High | $48.58 | $169.55 |
52-Week Low | $3.93 | $104.99 |
Typical Hold Time | 15 Days | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CONL (GraniteShares 2x Long COIN Daily ETF) trades at $5.41, up 3.44% today, but technical indicators show a bearish trend with moving averages signaling sell pressure. The ETF, which provides 2x daily leveraged exposure to Coinbase Global stock, faces volatility from its underlying asset's performance. Recent news highlights significant price gaps and volume spikes, with the stock previously gapping up to $6.44 on October 1, 2026.
The outlook remains high-risk due to leveraged structure amplifying Coinbase's volatility. Investment opportunity exists for short-term traders betting on Coinbase rebounds, but risks include rapid decay from daily rebalancing and crypto market downturns. Long-term holders face erosion from volatility drag, requiring careful risk management.
XBI trades at $153.34, up 2.07% today, but faces bearish technical signals with 17 sell indicators versus 4 buys. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from recent M&A activity and positive clinical trial catalysts. Current price sits near resistance at $154, with support at $147.
Biotech sector optimism is growing with cancer vaccine breakthroughs and improved capital access, though XBI's 0.35% expense ratio is higher than broader healthcare ETFs. Key risks include sector volatility and regulatory uncertainty, while analyst consensus remains neutral with 100% hold rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About GraniteShares 2x Long COIN Daily ETF
CONL is a leveraged ETF that seeks to provide two times (2x) the daily performance of Coinbase Global (COIN) stock. It is designed for investors seeking magnified short-term exposure to the price movements of Coinbase.
Read more on CONL →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
